Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial

The heart failure field has finally started to see progress in recent years, as drugs such as Novartis’ Entresto have bucked the history of failure. Yet, the focus remains largely on the symptoms. Heart failure is a disease that is controlled, not cured. Cardior Pharmaceuticals has a bigger goal—and has persuaded investors to commit €64 million ($75 million) to support its ambitions.